Form 8-K ANAPTYSBIO, INC For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
November 6, 2024 6:12 AM ESTH.C. Wainwright analyst Emily Bodnar lowered the price target on AnaptysBio (NASDAQ: ANAB) to $52.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "3Q24 financial recap; lowering PT to $52 from $55. AnaptysBio had 3Q24 total operating expenses of $52.8M, which were slightly... More
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
November 6, 2024 5:58 AM ESTLeerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More
